167 related articles for article (PubMed ID: 30328116)
1. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
[No Abstract] [Full Text] [Related]
2. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
3. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract][Full Text] [Related]
5. Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.
Jiang TT; Kruglov O; Akilov OE
Blood Adv; 2024 May; 8(10):2384-2397. PubMed ID: 38489234
[TBL] [Abstract][Full Text] [Related]
6. Emergence of Photosensitivity with Decreased Treg Cells in a Patient with Mycosis Fungoides Treated with Anti-CC Chemokine Receptor 4 Antibody Mogamulizumab.
Tatsuno K; Sano T; Fukuchi K; Kuriyama S; Aoshima M; Kasuya A; Ikeya S; Fujiyama T; Ito T; Tokura Y
Acta Derm Venereol; 2016 Mar; 96(3):420-1. PubMed ID: 26463269
[No Abstract] [Full Text] [Related]
7. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
8. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
9. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
Algarni AS; Ram-Wolff C; Bagot M; De Masson A
Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
13. Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.
Ricci C; Pileri A; Agostinelli C; Ambrosi F; Zinzani PL; Sabattini E
J Dtsch Dermatol Ges; 2018 Oct; 16(10):1263-1265. PubMed ID: 30277017
[No Abstract] [Full Text] [Related]
14. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
[TBL] [Abstract][Full Text] [Related]
15. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
[No Abstract] [Full Text] [Related]
16. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
Kanno K; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
[No Abstract] [Full Text] [Related]
17. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.
Hotz C; Ingen-Housz-Oro S; Tran Van Nhieu J; Charlier C; Foulet F; Rahmouni A; Zegai B; Duong TA; Wolkenstein P; Bagot M; Chosidow O
Eur J Dermatol; 2011; 21(6):1018-20. PubMed ID: 21926045
[No Abstract] [Full Text] [Related]
18. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
Nevet MJ; Zuckerman T; Sahar D; Bergman R
Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of CC chemokine receptor 4 and CXC chemokine receptor 3 ligands in CD8(+) Sézary syndrome.
Uchi H; Hayashida S; Takahara M; Moroi Y; Furue M
Acta Derm Venereol; 2012 May; 92(3):280-1. PubMed ID: 22293715
[No Abstract] [Full Text] [Related]
20. Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Miyagaki T; Sugaya M; Oka T; Fujita H; Sato S
Br J Dermatol; 2015 Aug; 173(2):620-2. PubMed ID: 25640919
[No Abstract] [Full Text] [Related]
[Next] [New Search]